The Only Global RAS Dedicated Conference is Returning in 2022 with the 3rd RAS/MAPK Pathway Targeted Drug Discovery Summit!

Year on year, we are proud to unite the leading frontiers of the RAS industry to showcase expertise, technical data and pipeline updates, all geared toward accelerating the discovery and development of anti-RAS therapies.

This February 2022, the summit returns to shine a spotlight onto pioneering discoveries and innovative strategies to target RAS, including a focus on success in targeting mutations beyond G12C and efforts to shut down the RAS/MAPK pathway at every turn.

As the industry springboards off the significant success of G12C covalent inhibitors against KRAS mutant cancers, leading experts are now shifting focus toward next-generation anti-RAS drugs, considering how we can leverage the RAS signaling pathway to treat all RAS mutant cancers, and overcome the critical escape mechanisms leading to treatment resistance.

To know more visit: https://ter.li/8ljo2k